Biogen Reports Quarterly Revenues of $3.1 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Biogen (BIIB) PT Lowered to $311 at RBC Capital
April 25, 2018 7:43 AM EDTRBC Capital lowered its price target on Biogen (NASDAQ: BIIB) to $311.00 (from $316.00) while maintaining a Sector Perform rating.
Analyst Brian Abrahams said Q1 softness stems from Spinraza and seasonality.
... MoreBiogen (BIIB) PT Lowered to $375 at Oppenheimer
April 25, 2018 7:15 AM EDTOppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "A solid 1Q update addressed investor concerns on multiple fronts with decent financial results featuring an EPS beat of $6.05 vs $5.93E consensus and... More
Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q
April 24, 2018 8:48 AM EDTPiper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.
BIIB's anti-CD20... More
